{
  "links": "https://www.ycombinator.com/companies/nuntius-therapeutics",
  "name": "Nuntius Therapeutics",
  "headline": "Cell-specific genetic medicines",
  "batch": "W21",
  "description": null,
  "activity_status": "Active",
  "website": "http://www.nuntiustx.com",
  "founded_date": 2021.0,
  "team_size": 2.0,
  "location": "London, United Kingdom",
  "group_partner": "Jared Friedman",
  "group_partner_yc": "https://www.ycombinator.com/people/jared-friedman",
  "company_linkedin": null,
  "company_twitter": null,
  "tags": "industry:gene-therapy; industry:nanomedicine",
  "founders": [],
  "status": true,
  "markdown": "raw_markdown='[Skip to content](http://www.nuntiustx.com/<#content>)\\n[ ](http://www.nuntiustx.com/</>)\\n[ ](http://www.nuntiustx.com/</>)\\n[ ](http://www.nuntiustx.com/</>)\\n  * [Home](http://www.nuntiustx.com/</#home>)\\n  * [Science](http://www.nuntiustx.com/</#science>)\\n  * [About Us](http://www.nuntiustx.com/</#about-us>)\\n  * [Media](http://www.nuntiustx.com/</#media>)\\n  * [Careers](http://www.nuntiustx.com/</#careers>)\\n\\n\\nMenu\\n  * [Home](http://www.nuntiustx.com/</#home>)\\n  * [Science](http://www.nuntiustx.com/</#science>)\\n  * [About Us](http://www.nuntiustx.com/</#about-us>)\\n  * [Media](http://www.nuntiustx.com/</#media>)\\n  * [Careers](http://www.nuntiustx.com/</#careers>)\\n\\n\\n[ ](http://www.nuntiustx.com/</>)\\n[ ](http://www.nuntiustx.com/</>)\\n[ ](http://www.nuntiustx.com/</>)\\n  * [Home](http://www.nuntiustx.com/</#home>)\\n  * [Science](http://www.nuntiustx.com/</#science>)\\n  * [About Us](http://www.nuntiustx.com/</#about-us>)\\n  * [Media](http://www.nuntiustx.com/</#media>)\\n  * [Careers](http://www.nuntiustx.com/</#careers>)\\n\\n\\nMenu\\n  * [Home](http://www.nuntiustx.com/</#home>)\\n  * [Science](http://www.nuntiustx.com/</#science>)\\n  * [About Us](http://www.nuntiustx.com/</#about-us>)\\n  * [Media](http://www.nuntiustx.com/</#media>)\\n  * [Careers](http://www.nuntiustx.com/</#careers>)\\n\\n\\n# Genetic medicines to cure patients with life-threatening diseases\\n## We develop transformative mRNA therapies by leveraging our ground-breaking proprietary delivery technology, machine learning and superior nucleic acid engineering.\\n### Delivery development\\nOur programmable, scalable, and non-immunogenic nanocarriers can target tissues and cell types beyond the liver and highly outperform leading delivery technologies.\\n### Machine learning\\nOur trained ML models predict carrier quality and performance to guide us in choosing the best candidates from a library of millions of distinct carriers. [See Publication →](http://www.nuntiustx.com/<https:/onlinelibrary.wiley.com/doi/epdf/10.1002/advs.202401935>)\\n### Genetic payload engineering\\nWe can design and engineer mRNA with highly superior protein expression levels compared to mRNA therapeutics used in the clinic. \\n### Drug development\\nCurrently, our primary focus is on advancing a pipeline of therapies targeting cancer, lung diseases and neurodegenerative diseases. \\n## About Us\\nWe are a team of passionate scientists and entrepreneurs, collaborating with expert scientific and business advisors.\\n### [Phoebe Knight ](http://www.nuntiustx.com/<https:/www.linkedin.com/in/phoebe-knight-42ba25201/>)\\n#### Delivery Chemistry\\n### [Liam Martin, PhD ](http://www.nuntiustx.com/<https:/www.linkedin.com/in/liam-martin-42992355/>)\\n#### Delivery Chemistry\\n### [Parisa Samangouei, PhD ](http://www.nuntiustx.com/<https:/www.linkedin.com/in/parisa-samangouei-phd-8ba88153/>)\\n#### Delivery Biology\\n### [Aaqib Ladak ](http://www.nuntiustx.com/<https:/www.linkedin.com/in/aaqib-ladak-a0b651157/>)\\n#### Delivery Biology\\n### [Benita Nagel ](http://www.nuntiustx.com/<https:/www.linkedin.com/in/benita-nagel/>)\\n#### Co-founder & CEO\\n### [Albert Kwok, PhD ](http://www.nuntiustx.com/<https:/www.linkedin.com/in/albert-kwok-1344a858/>)\\n#### Co-founder & CSO\\n### [Mark Wolters, PhD ](http://www.nuntiustx.com/<https:/www.linkedin.com/in/mark-wolters-0061722>)\\n#### Business Development\\n### [Lawrence Billing, PhD ](http://www.nuntiustx.com/<https:/www.linkedin.com/in/lawrence-billing-7909059a/>)\\n#### Asset Development\\n### [Tristan Henser, PhD ](http://www.nuntiustx.com/<https:/www.linkedin.com/in/tristanhenser/>)\\n#### Machine Learning\\n### [Adam Leach, PhD ](http://www.nuntiustx.com/<https:/www.linkedin.com/in/adamleachphd/>)\\n#### mRNA Engineering\\n### [Phoebe Knight ](http://www.nuntiustx.com/<https:/www.linkedin.com/in/phoebe-knight-42ba25201/>)\\n#### Delivery Chemistry\\n### [Liam Martin, PhD ](http://www.nuntiustx.com/<https:/www.linkedin.com/in/liam-martin-42992355/>)\\n#### Delivery Chemistry\\n### [Parisa Samangouei, PhD ](http://www.nuntiustx.com/<https:/www.linkedin.com/in/parisa-samangouei-phd-8ba88153/>)\\n#### Delivery Biology\\n### [Aaqib Ladak ](http://www.nuntiustx.com/<https:/www.linkedin.com/in/aaqib-ladak-a0b651157/>)\\n#### Delivery Biology\\n### [Benita Nagel ](http://www.nuntiustx.com/<https:/www.linkedin.com/in/benita-nagel/>)\\n#### Co-founder & CEO\\n### [Albert Kwok, PhD ](http://www.nuntiustx.com/<https:/www.linkedin.com/in/albert-kwok-1344a858/>)\\n#### Co-founder & CSO\\n### [Mark Wolters, PhD ](http://www.nuntiustx.com/<https:/www.linkedin.com/in/mark-wolters-0061722>)\\n#### Business Development\\n### [Lawrence Billing, PhD ](http://www.nuntiustx.com/<https:/www.linkedin.com/in/lawrence-billing-7909059a/>)\\n#### Asset Development\\n## Media\\n![](https://nuntiustx.com/wp-content/uploads/2024/08/PT-300x81.png)\\nNews\\nAugust 16, 2024\\n### Nuntius partners with Taiho to develop mRNA cancer therapies\\n[ Read More ](http://www.nuntiustx.com/<https:/www.pharmaceutical-technology.com/news/nuntius-partners-taiho-to-develop-mrna-cancer-therapies/>)\\n![](https://nuntiustx.com/wp-content/uploads/2024/08/PW3-e1724610201212-300x119.png)\\nNews\\nAugust 15, 2024\\n### Taiho teams up with Nuntius for cell-specific mRNA delivery\\n[ Read More ](http://www.nuntiustx.com/<https:/firstwordpharma.com/story/5885938>)\\n![](https://nuntiustx.com/wp-content/uploads/2024/08/business-wire-1024x512-20210930-e1724691440193-300x60.png)\\nPress Release\\nAugust 15, 2024\\n### Nuntius Therapeutics announces collaboration with Taiho Pharmaceutical to develop next-generation mRNA therapies using Nuntius’ proprietary cell-specific delivery technology\\n[ Read More ](http://www.nuntiustx.com/<https:/www.businesswire.com/news/home/20240815823712/en/Nuntius-Therapeutics-Announces-Collaboration-with-Taiho-Pharmaceutical-to-Develop-Next-Generation-mRNA-Therapies-Using-Nuntius%E2%80%99-Proprietary-Cell-Specific-Delivery-Technology>)\\n![](https://nuntiustx.com/wp-content/uploads/2024/06/Advanced-Science-300x122.png)\\nPublication\\nJune 5, 2024\\n### In Silico Screening Accelerates Nanocarrier Design for Efficient mRNA Delivery\\n[ Read More ](http://www.nuntiustx.com/<https:/onlinelibrary.wiley.com/doi/epdf/10.1002/advs.202401935>)\\n![](https://nuntiustx.com/wp-content/uploads/2024/08/BC-300x33.png)\\nNews\\nAugust 20, 2024\\n### Deals Report: Delivery play Nuntius out of stealth with Taiho cancer deal\\n[ Read More ](http://www.nuntiustx.com/<https:/www.biocentury.com/article/653293/deals-report-delivery-play-nuntius-out-of-stealth-with-taiho-cancer-deal>)\\n![](https://nuntiustx.com/wp-content/uploads/2024/08/GEN-300x54.png)\\nNews\\nAugust 16, 2024\\n### Nuntius Therapeutics Emerges from Stealth, Announces Taiho Pharmaceutical Partnership\\n[ Read More ](http://www.nuntiustx.com/<https:/www.genengnews.com/topics/cancer/nuntius-therapeutics-emerges-from-stealth-announces-taiho-pharmaceutical-partnership/>)\\n![](https://nuntiustx.com/wp-content/uploads/2024/08/PT-300x81.png)\\nNews\\nAugust 16, 2024\\n### Nuntius partners with Taiho to develop mRNA cancer therapies\\n[ Read More ](http://www.nuntiustx.com/<https:/www.pharmaceutical-technology.com/news/nuntius-partners-taiho-to-develop-mrna-cancer-therapies/>)\\n![](https://nuntiustx.com/wp-content/uploads/2024/08/PW3-e1724610201212-300x119.png)\\nNews\\nAugust 15, 2024\\n### Taiho teams up with Nuntius for cell-specific mRNA delivery\\n[ Read More ](http://www.nuntiustx.com/<https:/firstwordpharma.com/story/5885938>)\\n![](https://nuntiustx.com/wp-content/uploads/2024/08/business-wire-1024x512-20210930-e1724691440193-300x60.png)\\nPress Release\\nAugust 15, 2024\\n### Nuntius Therapeutics announces collaboration with Taiho Pharmaceutical to develop next-generation mRNA therapies using Nuntius’ proprietary cell-specific delivery technology\\n[ Read More ](http://www.nuntiustx.com/<https:/www.businesswire.com/news/home/20240815823712/en/Nuntius-Therapeutics-Announces-Collaboration-with-Taiho-Pharmaceutical-to-Develop-Next-Generation-mRNA-Therapies-Using-Nuntius%E2%80%99-Proprietary-Cell-Specific-Delivery-Technology>)\\n![](https://nuntiustx.com/wp-content/uploads/2024/06/Advanced-Science-300x122.png)\\nPublication\\nJune 5, 2024\\n### In Silico Screening Accelerates Nanocarrier Design for Efficient mRNA Delivery\\n[ Read More ](http://www.nuntiustx.com/<https:/onlinelibrary.wiley.com/doi/epdf/10.1002/advs.202401935>)\\n![](https://nuntiustx.com/wp-content/uploads/2024/08/BC-300x33.png)\\nNews\\nAugust 20, 2024\\n### Deals Report: Delivery play Nuntius out of stealth with Taiho cancer deal\\n[ Read More ](http://www.nuntiustx.com/<https:/www.biocentury.com/article/653293/deals-report-delivery-play-nuntius-out-of-stealth-with-taiho-cancer-deal>)\\n![](https://nuntiustx.com/wp-content/uploads/2024/08/GEN-300x54.png)\\nNews\\nAugust 16, 2024\\n### Nuntius Therapeutics Emerges from Stealth, Announces Taiho Pharmaceutical Partnership\\n[ Read More ](http://www.nuntiustx.com/<https:/www.genengnews.com/topics/cancer/nuntius-therapeutics-emerges-from-stealth-announces-taiho-pharmaceutical-partnership/>)\\n![](https://nuntiustx.com/wp-content/uploads/2024/08/PT-300x81.png)\\nNews\\nAugust 16, 2024\\n### Nuntius partners with Taiho to develop mRNA cancer therapies\\n[ Read More ](http://www.nuntiustx.com/<https:/www.pharmaceutical-technology.com/news/nuntius-partners-taiho-to-develop-mrna-cancer-therapies/>)\\n![](https://nuntiustx.com/wp-content/uploads/2024/08/PW3-e1724610201212-300x119.png)\\nNews\\nAugust 15, 2024\\n### Taiho teams up with Nuntius for cell-specific mRNA delivery\\n[ Read More ](http://www.nuntiustx.com/<https:/firstwordpharma.com/story/5885938>)\\n## Join our team\\nWe are looking for exceptional individuals who want to push the frontiers of science and are driven by patient outcome. Check out our open positions or email us at careers@nuntiustx.com.\\n![](https://nuntiustx.com/wp-content/uploads/2024/05/nuntius-loops-1-768x781.png)\\n![](https://nuntiustx.com/wp-content/uploads/2024/05/Lawrence-and-Marina-in-Lab-1024x682.jpg)\\n![](https://nuntiustx.com/wp-content/uploads/2024/05/nuntius-loops-2-768x534.png)\\nNuntius Therapeutics Inc.Delaware, United States\\ninfo@nuntiustx.com\\n[Privacy Policy](http://www.nuntiustx.com/</privacy-policy/>)\\nNuntius Therapeutics Ltd.London, United Kingdom\\n©2025 Nuntius \\n' markdown_with_citations='Skip to content⟨1⟩\\n ⟨2⟩\\n ⟨2⟩\\n ⟨2⟩\\n  * Home⟨3⟩\\n  * Science⟨4⟩\\n  * About Us⟨5⟩\\n  * Media⟨6⟩\\n  * Careers⟨7⟩\\n\\n\\nMenu\\n  * Home⟨3⟩\\n  * Science⟨4⟩\\n  * About Us⟨5⟩\\n  * Media⟨6⟩\\n  * Careers⟨7⟩\\n\\n\\n ⟨2⟩\\n ⟨2⟩\\n ⟨2⟩\\n  * Home⟨3⟩\\n  * Science⟨4⟩\\n  * About Us⟨5⟩\\n  * Media⟨6⟩\\n  * Careers⟨7⟩\\n\\n\\nMenu\\n  * Home⟨3⟩\\n  * Science⟨4⟩\\n  * About Us⟨5⟩\\n  * Media⟨6⟩\\n  * Careers⟨7⟩\\n\\n\\n# Genetic medicines to cure patients with life-threatening diseases\\n## We develop transformative mRNA therapies by leveraging our ground-breaking proprietary delivery technology, machine learning and superior nucleic acid engineering.\\n### Delivery development\\nOur programmable, scalable, and non-immunogenic nanocarriers can target tissues and cell types beyond the liver and highly outperform leading delivery technologies.\\n### Machine learning\\nOur trained ML models predict carrier quality and performance to guide us in choosing the best candidates from a library of millions of distinct carriers. See Publication →⟨8⟩\\n### Genetic payload engineering\\nWe can design and engineer mRNA with highly superior protein expression levels compared to mRNA therapeutics used in the clinic. \\n### Drug development\\nCurrently, our primary focus is on advancing a pipeline of therapies targeting cancer, lung diseases and neurodegenerative diseases. \\n## About Us\\nWe are a team of passionate scientists and entrepreneurs, collaborating with expert scientific and business advisors.\\n### Phoebe Knight ⟨9⟩\\n#### Delivery Chemistry\\n### Liam Martin, PhD ⟨10⟩\\n#### Delivery Chemistry\\n### Parisa Samangouei, PhD ⟨11⟩\\n#### Delivery Biology\\n### Aaqib Ladak ⟨12⟩\\n#### Delivery Biology\\n### Benita Nagel ⟨13⟩\\n#### Co-founder & CEO\\n### Albert Kwok, PhD ⟨14⟩\\n#### Co-founder & CSO\\n### Mark Wolters, PhD ⟨15⟩\\n#### Business Development\\n### Lawrence Billing, PhD ⟨16⟩\\n#### Asset Development\\n### Tristan Henser, PhD ⟨17⟩\\n#### Machine Learning\\n### Adam Leach, PhD ⟨18⟩\\n#### mRNA Engineering\\n### Phoebe Knight ⟨9⟩\\n#### Delivery Chemistry\\n### Liam Martin, PhD ⟨10⟩\\n#### Delivery Chemistry\\n### Parisa Samangouei, PhD ⟨11⟩\\n#### Delivery Biology\\n### Aaqib Ladak ⟨12⟩\\n#### Delivery Biology\\n### Benita Nagel ⟨13⟩\\n#### Co-founder & CEO\\n### Albert Kwok, PhD ⟨14⟩\\n#### Co-founder & CSO\\n### Mark Wolters, PhD ⟨15⟩\\n#### Business Development\\n### Lawrence Billing, PhD ⟨16⟩\\n#### Asset Development\\n## Media\\n![](https://nuntiustx.com/wp-content/uploads/2024/08/PT-300x81.png)\\nNews\\nAugust 16, 2024\\n### Nuntius partners with Taiho to develop mRNA cancer therapies\\n Read More ⟨19⟩\\n![](https://nuntiustx.com/wp-content/uploads/2024/08/PW3-e1724610201212-300x119.png)\\nNews\\nAugust 15, 2024\\n### Taiho teams up with Nuntius for cell-specific mRNA delivery\\n Read More ⟨20⟩\\n![](https://nuntiustx.com/wp-content/uploads/2024/08/business-wire-1024x512-20210930-e1724691440193-300x60.png)\\nPress Release\\nAugust 15, 2024\\n### Nuntius Therapeutics announces collaboration with Taiho Pharmaceutical to develop next-generation mRNA therapies using Nuntius’ proprietary cell-specific delivery technology\\n Read More ⟨21⟩\\n![](https://nuntiustx.com/wp-content/uploads/2024/06/Advanced-Science-300x122.png)\\nPublication\\nJune 5, 2024\\n### In Silico Screening Accelerates Nanocarrier Design for Efficient mRNA Delivery\\n Read More ⟨8⟩\\n![](https://nuntiustx.com/wp-content/uploads/2024/08/BC-300x33.png)\\nNews\\nAugust 20, 2024\\n### Deals Report: Delivery play Nuntius out of stealth with Taiho cancer deal\\n Read More ⟨22⟩\\n![](https://nuntiustx.com/wp-content/uploads/2024/08/GEN-300x54.png)\\nNews\\nAugust 16, 2024\\n### Nuntius Therapeutics Emerges from Stealth, Announces Taiho Pharmaceutical Partnership\\n Read More ⟨23⟩\\n![](https://nuntiustx.com/wp-content/uploads/2024/08/PT-300x81.png)\\nNews\\nAugust 16, 2024\\n### Nuntius partners with Taiho to develop mRNA cancer therapies\\n Read More ⟨19⟩\\n![](https://nuntiustx.com/wp-content/uploads/2024/08/PW3-e1724610201212-300x119.png)\\nNews\\nAugust 15, 2024\\n### Taiho teams up with Nuntius for cell-specific mRNA delivery\\n Read More ⟨20⟩\\n![](https://nuntiustx.com/wp-content/uploads/2024/08/business-wire-1024x512-20210930-e1724691440193-300x60.png)\\nPress Release\\nAugust 15, 2024\\n### Nuntius Therapeutics announces collaboration with Taiho Pharmaceutical to develop next-generation mRNA therapies using Nuntius’ proprietary cell-specific delivery technology\\n Read More ⟨21⟩\\n![](https://nuntiustx.com/wp-content/uploads/2024/06/Advanced-Science-300x122.png)\\nPublication\\nJune 5, 2024\\n### In Silico Screening Accelerates Nanocarrier Design for Efficient mRNA Delivery\\n Read More ⟨8⟩\\n![](https://nuntiustx.com/wp-content/uploads/2024/08/BC-300x33.png)\\nNews\\nAugust 20, 2024\\n### Deals Report: Delivery play Nuntius out of stealth with Taiho cancer deal\\n Read More ⟨22⟩\\n![](https://nuntiustx.com/wp-content/uploads/2024/08/GEN-300x54.png)\\nNews\\nAugust 16, 2024\\n### Nuntius Therapeutics Emerges from Stealth, Announces Taiho Pharmaceutical Partnership\\n Read More ⟨23⟩\\n![](https://nuntiustx.com/wp-content/uploads/2024/08/PT-300x81.png)\\nNews\\nAugust 16, 2024\\n### Nuntius partners with Taiho to develop mRNA cancer therapies\\n Read More ⟨19⟩\\n![](https://nuntiustx.com/wp-content/uploads/2024/08/PW3-e1724610201212-300x119.png)\\nNews\\nAugust 15, 2024\\n### Taiho teams up with Nuntius for cell-specific mRNA delivery\\n Read More ⟨20⟩\\n## Join our team\\nWe are looking for exceptional individuals who want to push the frontiers of science and are driven by patient outcome. Check out our open positions or email us at careers@nuntiustx.com.\\n![](https://nuntiustx.com/wp-content/uploads/2024/05/nuntius-loops-1-768x781.png)\\n![](https://nuntiustx.com/wp-content/uploads/2024/05/Lawrence-and-Marina-in-Lab-1024x682.jpg)\\n![](https://nuntiustx.com/wp-content/uploads/2024/05/nuntius-loops-2-768x534.png)\\nNuntius Therapeutics Inc.Delaware, United States\\ninfo@nuntiustx.com\\nPrivacy Policy⟨24⟩\\nNuntius Therapeutics Ltd.London, United Kingdom\\n©2025 Nuntius \\n' references_markdown='\\n\\n## References\\n\\n⟨1⟩ http://www.nuntiustx.com/<#content>: Skip to content\\n⟨2⟩ http://www.nuntiustx.com/</>:  \\n⟨3⟩ http://www.nuntiustx.com/</#home>: Home\\n⟨4⟩ http://www.nuntiustx.com/</#science>: Science\\n⟨5⟩ http://www.nuntiustx.com/</#about-us>: About Us\\n⟨6⟩ http://www.nuntiustx.com/</#media>: Media\\n⟨7⟩ http://www.nuntiustx.com/</#careers>: Careers\\n⟨8⟩ http://www.nuntiustx.com/<https:/onlinelibrary.wiley.com/doi/epdf/10.1002/advs.202401935>: See Publication →\\n⟨9⟩ http://www.nuntiustx.com/<https:/www.linkedin.com/in/phoebe-knight-42ba25201/>: Phoebe Knight \\n⟨10⟩ http://www.nuntiustx.com/<https:/www.linkedin.com/in/liam-martin-42992355/>: Liam Martin, PhD \\n⟨11⟩ http://www.nuntiustx.com/<https:/www.linkedin.com/in/parisa-samangouei-phd-8ba88153/>: Parisa Samangouei, PhD \\n⟨12⟩ http://www.nuntiustx.com/<https:/www.linkedin.com/in/aaqib-ladak-a0b651157/>: Aaqib Ladak \\n⟨13⟩ http://www.nuntiustx.com/<https:/www.linkedin.com/in/benita-nagel/>: Benita Nagel \\n⟨14⟩ http://www.nuntiustx.com/<https:/www.linkedin.com/in/albert-kwok-1344a858/>: Albert Kwok, PhD \\n⟨15⟩ http://www.nuntiustx.com/<https:/www.linkedin.com/in/mark-wolters-0061722>: Mark Wolters, PhD \\n⟨16⟩ http://www.nuntiustx.com/<https:/www.linkedin.com/in/lawrence-billing-7909059a/>: Lawrence Billing, PhD \\n⟨17⟩ http://www.nuntiustx.com/<https:/www.linkedin.com/in/tristanhenser/>: Tristan Henser, PhD \\n⟨18⟩ http://www.nuntiustx.com/<https:/www.linkedin.com/in/adamleachphd/>: Adam Leach, PhD \\n⟨19⟩ http://www.nuntiustx.com/<https:/www.pharmaceutical-technology.com/news/nuntius-partners-taiho-to-develop-mrna-cancer-therapies/>:  Read More \\n⟨20⟩ http://www.nuntiustx.com/<https:/firstwordpharma.com/story/5885938>:  Read More \\n⟨21⟩ http://www.nuntiustx.com/<https:/www.businesswire.com/news/home/20240815823712/en/Nuntius-Therapeutics-Announces-Collaboration-with-Taiho-Pharmaceutical-to-Develop-Next-Generation-mRNA-Therapies-Using-Nuntius%E2%80%99-Proprietary-Cell-Specific-Delivery-Technology>:  Read More \\n⟨22⟩ http://www.nuntiustx.com/<https:/www.biocentury.com/article/653293/deals-report-delivery-play-nuntius-out-of-stealth-with-taiho-cancer-deal>:  Read More \\n⟨23⟩ http://www.nuntiustx.com/<https:/www.genengnews.com/topics/cancer/nuntius-therapeutics-emerges-from-stealth-announces-taiho-pharmaceutical-partnership/>:  Read More \\n⟨24⟩ http://www.nuntiustx.com/</privacy-policy/>: Privacy Policy\\n' fit_markdown='' fit_html=''",
  "generated_description": "### Overview of Nuntius Therapeutics\n\n**Nuntius Therapeutics** is a cutting-edge biotech startup founded in **2021**, based in **London, UK**. This company stands at the forefront of the **gene therapy** and **nanomedicine** space, emerging as a notable member of **Y Combinator's W21 batch**. With a lean team of just two passionate employees, Nuntius is focused on revolutionizing the way we approach genetic medicines.\n\n**Mission and Focus**\n\nNuntius is dedicated to developing **cell-specific genetic medicines**, primarily utilizing their innovative **mRNA therapies**. Their mission is straightforward yet monumental: to create transformative genetic treatments for patients suffering from life-threatening diseases. Their current research pipeline targets serious conditions such as **cancer**, **lung diseases**, and **neurodegenerative diseases**.\n\n### The Science Behind Nuntius\n\n1. **Proprietary Delivery Technology**: Nuntius has engineered proprietary, non-immunogenic **nanocarriers** capable of targeting a variety of cell types beyond the liver, which is a significant limitation of many existing delivery systems.\n\n2. **Machine Learning Integration**: The firm's methodologies integrate advanced **machine learning** to select the most effective nanocarrier candidates from a library of millions, ensuring that the mRNA therapeutics have the best possible delivery and efficacy.\n\n3. **Nucleic Acid Engineering**: Nuntius's expertise in **genetic payload engineering** allows them to design mRNA constructs that achieve superior protein expression levels compared to current therapies on the market.\n\n### Leadership and Team\n\nThe company is co-founded by **Benita Nagel (CEO)** and **Albert Kwok (CSO)**, both of whom lead a diverse group of experts, including chemists and biologists specializing in delivery systems, machine learning, and mRNA engineering. Their collaborative atmosphere is bolstered by a group of capable scientific and business advisors.\n\n### Recent Developments\n\nRecently, Nuntius has made waves by partnering with **Taiho Pharmaceutical** to advance mRNA cancer therapies. This collaboration marks a significant step as they bring their proprietary delivery technology into real-world applications.\n\n### Conclusion\n\nIn a nutshell, Nuntius Therapeutics is a dynamic and ambitious player in the biotech realm, committed to pushing the boundaries of genetic medicine. Their innovative approaches and strategic partnerships position them well for impacting how we understand and treat some of the most challenging diseases of our time. To learn more, visit their official website at [Nuntius Therapeutics](http://www.nuntiustx.com)."
}